

Alliance Medical Acquisitionco Limited

Annual Report & Financial Statements

For the year ended 30 September 2020

Company number 06412789

Alliance Medical Acquisitionco Limited

DIRECTORS

H A D Marsh
M D Chapman
P P Van Der Westhuizen
S B Viranna (resigned 17 January 2020)

INDEPENDENT AUDITORS

Deloitte LLP
Four Brindleyplace
Birmingham
B1 2HZ

BANKERS

NatWest Bank plc
1 Town Hall Building
Banbury
Oxon
OX16 8JS

REGISTERED OFFICE

Iceni Centre
Warwick Technology Park
Warwick
Warwickshire
CV34 6DA
United Kingdom

Alliance Medical Acquisitionco Limited

STRATEGIC REPORT

PRINCIPAL ACTIVITY

The principal activity of the Company during the year is the provision of funding to fellow subsidiary undertakings of the Company's parent, Alliance Medical Group Limited.

REVIEW OF THE BUSINESS

As stated above the main focus of this company is provide funding as necessary around the Alliance Medical Group. The company does hold investments in some of the group companies and has various intercompany loans depending on the funding needs of the group. The company has continued to provide this support throughout this financial year.

The key performance indicators of the Company are:

	Year to 30 September 2020	Year to 30 September 2019
	£000	£000
Operating loss	(0.3)	-
Net assets	113,864	115,717

The company does not consider there to be any other key performance indicators relevant to the business.

RESULTS AND DIVIDENDS

The loss for the year amounted to £1,853,000 (year to 30 September 2019: loss of £3,291,000), the majority of this loss relates to the discounting of contingent consideration payable as well as amortisation of loan setup fees. During the year a dividend of £nil was paid (2019: £nil).

Alliance Medical Acquisitionco Limited

STRATEGIC REPORT (continued)

MANAGEMENT OF PRINCIPAL RISKS AND UNCERTAINTIES

The Company's Directors recognise the importance of sound risk management to the success of operations and accordingly set policies to mitigate the risks. The principal risks and uncertainties facing the Company and the potential impact and mitigation are summarised below.

Risk Category	Potential Impact	Mitigation
Exchange rate risk including economic risk following referendum decision to leave the European Union	Reduced profitability as a result of instability in the Sterling to Euro exchange rate	Hedging via a portion of a parent undertaking's borrowings being denominated in Euros.
Liquidity risk	Withdrawal of funding	Liquidity risk is managed at the Group level and includes regular monitoring of, and reporting compliance with, bank covenants both prospectively and retrospectively; Applying cash collection targets throughout the Group; Regular cash flow forecasting, with action taken if needed to re-time flows.
Counterparty credit risk	A fellow subsidiary undertaking may not satisfy its contractual obligations in meeting its inter-company liabilities	Counterparty credit risk is mitigated by ensuring that loans to fellow subsidiaries contribute to the long term success of the Group.

CAPITAL MANAGEMENT

The primary objective of the Company's capital management is to ensure that, there are sufficient funds available to subsidiary undertakings to support sustainable planned growth and expansion, by utilising the funding facilities available.

To maintain or adjust the capital structuring, the company may review the utilisation of bank funding facilities, hedging instruments and intergroup borrowings from its subsidiary undertakings.

Alliance Medical Acquisitionco Limited

STRATEGIC REPORT (continued)

SECTION 172(1) STATEMENT

In performing their duties under section 172, the directors of Alliance Medical Acquisitionco Limited have had regard to the matters set out in section 172(1) as follows:

The directors' approach

The Group operates on a decentralised basis, with the Board having established an organisational structure with clear reporting procedures, lines of responsibility and delegated authority. The Board is ultimately accountable to the Company's shareholders for setting the Company's strategy and for overseeing its financial and operational performance in line with the parent company's strategic objectives. Implementation of the Company's strategic objectives, as determined and overseen by the Board, is delegated to the local senior management teams within each region, who are also responsible for the day to day operational management of their businesses.

The Board cultivates strong relationships with key stakeholders so that it is well placed and sufficiently informed to take their considerations into account when making decisions where appropriate in order to discharge their legal obligations and to pursue the Company's strategic objectives. Our purpose is to create long-term value for stakeholders and in order to do this, we need to understand our stakeholders and what matters to them.

Maintaining our licence to operate

In executing our strategy, Directors must act in accordance with a set of general duties detailed in section 172 of the Companies Act 2006. These general duties include a duty to promote the success of the Company, and specifically to act in a way that the Director considers, in good faith, would be most likely to promote the success of the Company for the benefit of its shareholders as a whole and, in doing so, having regard (amongst other matters) to:

Board oversight and Decision making

The board meets on a regular basis to review performance, including:

- Clinical governance and quality measures
- Human resource implications
- Operational delivery
- Financial performance
- Progress towards strategic objectives

Key decisions are taken in these meetings, being those which are material or of strategic importance to the Group. These decisions are made in line with a Delegation of Authority as set by the Board of the ultimate parent company, Life Healthcare Group Holdings Limited ("Life Healthcare"). For decisions that do fall outside the Delegation of Authority, a recommendation is made by the Board to the appropriate sub-committee of Life Healthcare Group for further consideration.

Examples of key decisions taken during the year include:

Approval of 2021 budget

The board approved the final budget for the 12 months to September 2021, in September 2020, subject to the final approval of the Life Healthcare Group Board. The budget was based on business plans and targets for each main area of the Group, including any investments needed to fulfil these.

Capital investment in additional CT scanners

During the year the Company acquired additional CT scanners, in order to support various public healthcare providers' response to COVID-19, including within Nightingale Hospitals in England.

Alliance Medical Acquisitionco Limited

STRATEGIC REPORT (continued)

Key Stakeholders

As a healthcare provider, we have a large number of stakeholders, including patients, employees, regulators and commissioners, customers and suppliers.

Having regard to the need to foster the Company's business relationships with patients

Our patients are central to everything we do. The board receives regular updates on quality and compliance metrics so that the quality of services provided can be closely monitored. Patient feedback, both positive and negative, is essential for the development of our service and to ensure we are providing the best possible care for patients.

Having regard to the interests of the Company's employees

The Company employs clinical staff and administrative teams to support them and enable their focus on patient care.

The Company engages with employees through a number of channels, including the Employee Forum, operational team briefings, regular communications from the UK MD and updates through the intranet.

The Directors monitor the results of regular staff surveys, so that the board is able to discuss human resourcing matters with the interests of the employees at the centre. Engaging with our employees enables us to create an inclusive culture and a positive working environment.

Having regard to the need to foster the Company's business relationships with Regulators & Commissioners

As a provider of healthcare services, it is essential our services are provided in line with local regulator & commissioners needs. The Board will consider the requirements of regulators & commissioners when making decision on resource allocations.

Having regard to the need to foster the Company's business relationships with Customers

A close working relationship with our customers, who are predominantly public healthcare providers, helps us to better understand their needs. Our teams use their significant experience in providing high quality healthcare services to constantly refine what we do to provide continuous improvement in our service offering.

With respect to long term decisions

All major decisions are reviewed and validated by the directors at regular board meetings with all key decisions supported by detailed briefings identifying main issues, main recommendations, and alternatives considered and the likely long term impact on the company in respect of value creation, its environmental and community effect and any implications for key stakeholders.

With respect to high standards of business conduct

We acknowledge the responsibility we have to our local community in which we operate and given our global presence, our duty to act on an international scale. The vast majority of our workforce is drawn from local residence generating wealth in the areas we operate as well as bolstering employment opportunities.

Having regard to the need to act fairly as between members of the company

The ultimate parent undertaking is Life Healthcare Group Holdings Limited, incorporated in South Africa. The board at South Africa level are represented within Life UK Holdco Ltd and its subsidiaries as mutual directors sit on both boards. As a result the directors are fully aligned with its shareholders.

Alliance Medical Acquisitionco Limited

STRATEGIC REPORT (continued)

Having regard to the need to foster the Company's business relationships with Suppliers

The company has good relationships with its key suppliers and often works in partnership with them to deliver innovative solutions to better benefit other stakeholders.

Having regard to the need to foster the Company's business impacts on the environment

The Company recognises the serious threat posed by climate change and the urgent need for meaningful action. As part of their improvement plans, our businesses seek to reduce their GHG emissions over time through more efficient use of electricity, fuel and heat, and by increasing the proportion of renewable energy where commercially viable.

FUTURE DEVELOPMENTS

The Directors continue to seek opportunities to enhance shareholder value through investments.

Approved by the board on 23 December 2020 and signed on its behalf by:



H A D Marsh
Director

Iceni Centre
Warwick Technology Park
Warwick
CV34 6DA
United Kingdom

Alliance Medical Acquisitionco Limited

DIRECTORS' REPORT

The Directors present their report together with the audited financial statements for the year ended 30 September 2020.

FUTURE DEVELOPMENTS

The Directors continue to seek opportunities to enhance shareholder value by providing suitable finance to Group companies for the foreseeable future.

DIRECTORS AND THEIR INTERESTS

The Directors of the Company who were in office during the year and up to the date of signing the financial statements were as follows:

H A D Marsh
M D Chapman
P P Van Der Westhuizen

No Director is beneficially interested in the share capital of the Company.

DIRECTORS' AND OFFICERS' LIABILITY INSURANCE

During the year and at the date of approval of the financial statements there were insurance cover for Directors' and Officers' liability as permitted under section 232 (2) of the Companies Act 2006. These are third party indemnity policy and it's a Global policy arranged by the company's Ultimate Parent and controlling party, Life Healthcare Group Holdings Limited.

EMPLOYEE INVOLVEMENT

The Company itself do not employ any staff members other than the directors themselves. The wider Group attaches considerable importance to the involvement of its employees and has continued to keep them informed on matters affecting them as employees and on the various factors affecting the performance of the Group. Employees are consulted on issues directly affecting them wherever practicable, and senior managers and employee representatives from all areas of the business meet to discuss issues. In some areas of the business, employee surveys are undertaken, using an independent third party, and the results are shared with employees and are used to drive changes as required, and also outline the impact economic and financial factors on the company's performance. Some senior management are also involved in a share scheme to further encourage their involvement in the company's success.

EQUALITY

The wider Group is committed to ensuring that recruitment practices promote equality of opportunity in line with the 2010 Equality Act in the UK and relevant legislation in other regions in which the Group operates. The Group treats all applicants fairly regardless of their sex, sexual orientation, marital status, race, colour, nationality, ethnic or nation origin, religion, age, disability and union membership status. The Group ensures that no requirement or condition is imposed without justification, which could disadvantage an individual on any of the above grounds.

The Group continues to be supportive of the employment of disabled persons. Applications for employment from disabled persons are always fully considered, bearing in mind the aptitudes of the applicant concerned. In the event an existing member of staff becomes disabled, it is the Group's policy to provide continued employment wherever practicable in the same or alternative positions and appropriate training is arranged. It is the policy of the Group that the training, career development and promotion of disabled employees should, as far as possible, be identical to that of other employees.

Alliance Medical Acquisitionco Limited

DIRECTORS' REPORT (continued)

ENGAGEMENT WITH SUPPLIERS, CUSTOMERS AND OTHERS

For further detail on the business relationships of the group, please refer to the Section 172 statement in the strategic report shown on pages 5 to 7.

POLITICAL DONATIONS

The Company made £nil (2019: £nil) political donations during the year.

GOING CONCERN

The Directors performs regular assessments on the going concern status of the Company. These assessments take into consideration:

- current solvency of the Company;
- current liquidity position;
- available committed and uncommitted bank facilities;
- cash commitments for the next 12 months;
- bank covenants; and
- debt maturities.

As part of the assessments the board of directors has reviewed the Company budgets, forecasts, available cash resources and unutilised facilities as well as the debt maturity profile. The forecasts for the Company have been prepared, covering its future performance, capital and liquidity for a period of 12 months from the date of approval of these financial statements including performing sensitivity analyses. The expected future cash flows were adjusted to reflect the best estimate of the short and longer-term impact of the COVID-19 pandemic (the pandemic).

To ensure the Company has sufficient cash reserves, in addition to securing bank facilities at Life UK Holdco level, management has implemented a number of mitigating actions which include cost and cash preservation levers across the Group's operations.

The external debt used to provide funding for the Alliance Medical Group companies (of which this company is a subsidiary) sit outside of these financial statements (the external debt is recorded in Life UK Holdco Limited) and include covenants that must be met at various measurement points as defined in the contract for these facilities. These covenants are measured based on the results of the wider group- this being the group headed by Life Healthcare Group Holdings Limited. Life Healthcare Group Holdings Limited is the ultimate parent undertaking and controlling party of Alliance Medical Group limited. The wider group successfully refinanced this external debt during March 2020 and extended the Debt's maturities. This wider Group is in a strong financial position with net debt to normalised EBITDA as at 30 September 2020 at 2.96 times (2019: 1.96 times). Given the significant uncertainty caused by the pandemic, the wider Group pre-emptively negotiated amended bank covenants for the period up to 31 March 2021 and continue to monitor prospective compliance with such covenants. In addition, banking facilities have been increased and the wider Group's committed undrawn bank facilities as at 30 September 2020 are R6.3 billion.

The Director's assessments and sensitivity analysis show that the Company has sufficient accessible capital and liquidity to continue to meet its obligations as they fall due and as a result it is appropriate to prepare these consolidated financial statements on a going concern basis.

DIVIDENDS

During the period a dividend of £nil was paid (2019: £nil). There have been no dividends .proposed since the year end

FINANCIAL RISK MANAGEMENT

The principal risks and uncertainties facing the Company and the potential impact and mitigation are summarised in the Strategic Report.

Alliance Medical Acquisitionco Limited

DIRECTORS' REPORT (continued)

ENERGY AND CARBON REPORTING

The Company recognises the serious threat posed by climate change and the urgent need for meaningful action. As part of their improvement plans, our businesses seek to reduce their GHG emissions over time through more efficient use of electricity, fuel and heat, and by increasing the proportion of renewable energy where commercially viable.

Alliance Medical submitted its four-yearly ESOS2 Energy Consumption Report in December 2019. The report provides greater visibility of our energy use across all our supply channels. Alliance Medical is also required to submit a report in terms of government's streamlined energy and carbon reporting (SECR) framework for the first time this year, providing commentary on the practical changes undertaken to improve energy consumption and, consequently, our environmental footprint. We are also busy transforming our car fleet scheme to introduce electric vehicles.

Alliance Medical is particularly exposed to radioactive waste due to the nature of its business. We manage this carefully, along with the control and disposal of general, infectious and hazardous medical waste. We comply with international waste disposal guidelines and local in-country requirements throughout this process.

POST BALANCE SHEET EVENTS

The Covid pandemic is considered to remain a significant event after the balance sheet date, even though it has also impacted the group in this financial year. The impact of Covid is still being felt across the globe within the healthcare industry, including the countries that Alliance Medical Group operate in. Following the balance sheet date, a number of European Countries, including the UK, has entered second national lock down. The effects of Covid are still felt around the business, however volumes are almost back to 100% of pre-Covid levels and systems and protocols put in place during wave 1 of the pandemic now mean that the business can continue to operate at a more effective level during the ongoing Covid impacts. This is as well as opportunities taken as a result of the pandemic, have meant that the directors do not believe that the effects of Covid post the balance sheet date lead to a material impact in the numbers presented and therefore no adjustments are required.

As well as the above there are ongoing discussions between the UK and the EU in relation to a trade deal following the UK's exit from the EU effective from 1 January 2021. Currently there are no details regarding the likelihood or the contents of such a deal. As a result it cannot be estimated what impacts Brexit will have on the Company and therefore no changes have been made to these financial statements.

Alliance Medical Acquisitionco Limited

DIRECTORS' REPORT (continued)

AUDITORS

Each of the persons who is a director at the date of approval of this report confirms that:

- so far as the director is aware, there is no relevant audit information of which the Company's auditors are unaware; and
- the director has taken all the steps that he/she ought to have taken as a director in order to make himself/herself aware of any relevant audit information and to establish that the company's auditors are aware of that information.

This confirmation is given and should be interpreted in accordance with the provisions of s418 of the Companies Act 2006.

Deloitte LLP have expressed their willingness to continue in office as auditors and appropriate arrangements have been put in place for them to be deemed reappointed as auditors in the absence of an Annual General Meeting.

Approved by the Board on 23 December 2020 and signed on its behalf by:



H A D Marsh
Director
Iceni Centre
Warwick Technology Park
Warwick
CV34 6DA
United Kingdom

Alliance Medical Acquisitionco Limited

STATEMENT OF DIRECTORS' RESPONSIBILITIES

The directors are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have prepared the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law), including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland". Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing the financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- make judgements and accounting estimates that are reasonable and prudent; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Independent auditor's report to the members of Alliance Medical Acquisitionco Limited
Report on the audit of the financial statements

Opinion

In our opinion the financial statements of Alliance Medical Acquisitionco Limited (the 'company'):

- give a true and fair view of the state of the company's affairs as at 30 September 2020 and of its loss for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice, including Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland"; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

We have audited the financial statements which comprise:

- the profit and loss account;
- the balance sheet;
- the statement of changes in equity; and
- the related notes 1 to 16.

The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" (United Kingdom Generally Accepted Accounting Practice).

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor's responsibilities for the audit of the financial statements section of our report.

We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the Financial Reporting Council's (the 'FRC's') Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

We are required by ISAs (UK) to report in respect of the following matters where:

- the directors' use of the going concern basis of accounting in preparation of the financial statements is not appropriate; or
- the directors have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

We have nothing to report in respect of these matters.

Independent auditor's report to the members of Alliance Medical Acquisitionco Limited
Report on the audit of the financial statements (continued)

Other information

The directors are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in respect of these matters.

Responsibilities of directors

As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the FRC's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Independent auditor's report to the members of Alliance Medical Acquisitionco Limited
Report on the audit of the financial statements (continued)

Report on other legal and regulatory requirements

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the strategic report and the directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the strategic report and the directors' report have been prepared in accordance with applicable legal requirements.

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified any material misstatements in the strategic report or the directors' report.

Matters on which we are required to report by exception

Under the Companies Act 2006 we are required to report in respect of the following matters if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

We have nothing to report in respect of these matters.

Use of our report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Peter Gallimore, FCA (Senior statutory auditor)
For and on behalf of Deloitte LLP
Statutory Auditor
Birmingham, United Kingdom
December 2020

Alliance Medical Acquisitionco Limited

PROFIT AND LOSS ACCOUNT

for the year ended 30 September 2020

	Notes	Year ended 30 September 2020 £000	Year ended 30 September 2019 £000
Administrative expenses		(312)	-
OPERATING LOSS	4	(312)	-
Interest receivable and similar income	7	11,527	10,126
Interest payable and similar charges	8	(13,068)	(13,417)
LOSS BEFORE TAXATION		(1,853)	(3,291)
Tax on loss	9	-	-
LOSS FOR THE FINANCIAL PERIOD		(1,853)	(3,291)

The Company's activities all derive from continuing operations.

There is no other comprehensive income or expenses other than those included above and therefore a statement of comprehensive income has not been included in these financial statements.

There is no material difference between the loss before taxation and the loss for the financial periods stated above and their historical cost equivalents.

Alliance Medical Acquisitionco Limited

BALANCE SHEET As at 30 September 2020

Company registered number: 06412789

	Notes	At 30 September 2020 £000	At 30 September 2019 £000
FIXED ASSETS			
Investments	10	140,542	140,542
		140,542	140,542
CURRENT ASSETS			
Debtors: amounts falling due within one year	11	225,758	213,116
Cash at bank and in hand		24,467	11,353
		250,225	224,469
CREDITORS: amounts falling due within one year	12	(19,027)	(19,634)
NET CURRENT ASSETS		231,198	204,835
TOTAL ASSETS LESS CURRENT LIABILITIES		371,740	345,377
CREDITORS: amounts falling due after more than one year	12	(257,876)	(229,660)
NET ASSETS		113,864	115,717
CAPITAL AND RESERVES			
Called up share capital	13	147,537	147,537
Profit and loss account		(33,673)	(31,820)
TOTAL SHAREHOLDERS' FUNDS		113,864	115,717

The notes on pages 18 to 31 are an integral part of these financial statements.

These financial statements on pages 15 to 31 were approved by the Board of Directors on 23 December 2020 and were signed on its behalf by:



H A D Marsh
Director

Alliance Medical Acquisitionco Limited

STATEMENT OF CHANGES IN EQUITY

For the year ended 30 September 2020

	Called up share capital	Profit and loss account	Total Shareholders' funds
	£000	£000	£000
At 1 October 2018	147,537	(28,529)	119,008
Loss for the financial year	-	(3,291)	(3,291)
At 30 September 2019	147,537	(31,820)	115,717
Loss for the financial year	-	(1,853)	(1,853)
At 30 September 2020	147,537	(33,673)	113,864

Alliance Medical Acquisitionco Limited

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 30 September 2020

1. GENERAL INFORMATION

The Company is a private company limited by shares and is incorporated in the United Kingdom under Companies Act 2006 and registered in England. The address of the registered office and principal place of business is shown on page 2. The principal activity of the Company is shown in the Strategic Report on page 3.

2. STATEMENT OF COMPLIANCE

These financial statements have been prepared in accordance with applicable accounting standards in the United Kingdom, including Financial Reporting Standard 102 “The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland” (“FRS 102”) and the Companies Act 2006.

3. ACCOUNTING POLICIES

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the Company’s financial statements.

Basis of preparation

These financial statements have been prepared on a going concern basis under the historical cost convention.

Going Concern

The Directors performs regular assessments on the going concern status of the Company. These assessments take into consideration:

- current solvency of the Company;
- current liquidity position;
- available committed and uncommitted bank facilities;
- cash commitments for the next 12 months;
- bank covenants; and
- debt maturities.

As part of the assessments the board of directors has reviewed the Company budgets, forecasts, available cash resources and unutilised facilities as well as the debt maturity profile. The forecasts for the Company have been prepared, covering its future performance, capital and liquidity for a period of 12 months from the date of approval of these financial statements including performing sensitivity analyses. The expected future cash flows were adjusted to reflect the best estimate of the short and longer-term impact of the COVID-19 pandemic (the pandemic).

To ensure the Company has sufficient cash reserves, in addition to securing bank facilities at Life UK Holdco level, management has implemented a number of mitigating actions which include cost and cash preservation levers across the Group’s operations.

Alliance Medical Acquisitionco Limited

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 30 September 2020

3. ACCOUNTING POLICIES (continued)

The external debt used to provide funding for the Alliance Medical Group companies (of which this company is a subsidiary) sit outside of these financial statements (the external debt is recorded in Life UK Holdco Limited) and include covenants that must be met at various measurement points as defined in the contract for these facilities. These covenants are measured based on the results of the wider group- this being the group headed by Life Healthcare Group Holdings Limited. Life Healthcare Group Holdings Limited is the ultimate parent undertaking and controlling party of Alliance Medical Group limited. The wider group successfully refinanced this external debt during March 2020 and extended the Debt's maturities. This wider Group is in a strong financial position with net debt to normalised EBITDA as at 30 September 2020 at 2.96 times (2019: 1.96 times). Given the significant uncertainty caused by the pandemic, the wider Group pre-emptively negotiated amended bank covenants for the period up to 31 March 2021 and continue to monitor prospective compliance with such covenants. In addition, banking facilities have been increased and the wider Group's committed undrawn bank facilities as at 30 September 2020 are R6.3 billion.

The Director's assessments and sensitivity analysis show that the Company has sufficient accessible capital and liquidity to continue to meet its obligations as they fall due and as a result it is appropriate to prepare these consolidated financial statements on a going concern basis.

Basis of consolidation

Group financial statements have not been prepared as permitted by Section 400 of the Companies Act 2006, as the Company is a wholly owned subsidiary of Alliance Medical Group Limited, a company incorporated in England and Wales, from whose registered office Group financial statements may be obtained (Iceni Centre, Warwick Technology Park, Warwick, CV34 6DA, United Kingdom). Therefore these financial statements present information about the Company and not about its Group.

Exemptions

As a qualifying entity, the company has taken advantage of the disclosure exemptions available to it in respect of its separate financial statements. The Company is consolidated in the financial statements of its parent, Group Limited, which may be obtained at its registered address at The Iceni Centre, Warwick Technology Park, Warwick, Cv34 6DA.

The Company has taken advantage of the exemption provided in paragraph 1.12(b) of FRS 102 from preparing a Statement of Cash Flows.

The Company has taken advantage of the exemption provided in paragraph 4.12(a) of FRS 102 from preparing a reconciliation of the numbers of shares outstanding at the beginning and end of the period.

The Company has taken advantage of the exemption provided in paragraph 33.7 of FRS 102 from disclosing key management personnel compensation.

The Company has taken advantage of the exemption provided in paragraphs 11.39-11.48A and 12.26-12.29 of FRS 102 from disclosing certain financial instrument disclosures. The financial instrument disclosures are incorporated into the Group financial statements of the ultimate UK parent undertaking.

The Company has taken advantage of the exemption in paragraph 33.1(a) of FRS 102 from disclosing transactions with related parties that are other wholly owned members of the Alliance Medical Group Limited group.

Functional and presentation currency

The Company's functional and presentation currency is the pound sterling.

Alliance Medical Acquisitionco Limited

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 30 September 2020

3. ACCOUNTING POLICIES (continued)

Fixed asset investments

Investments in subsidiary undertakings are stated at cost less provision for impairment. Where part or all of the consideration for acquisitions is deferred or contingent on uncertain future events, the cost of acquisition recorded is a reasonable estimate of the fair value of amounts expected to be payable in the future, discounted to present value.

Impairment of assets

The carrying amounts of assets are reviewed at each balance sheet date to determine whether there is any indication of impairment. If any such indication exists, the asset's recoverable amount is estimated to determine the amount of impairment loss.

For the purpose of impairment testing of these assets, recoverable amount is determined on an individual asset basis unless the asset does not generate cash flows that are largely independent of those from other assets. If this is the case, recoverable amount is determined for the cost generating unit ("CGU") to which the asset belongs to. An asset's recoverable amount is the higher of the asset's, or CGU's, fair value less costs to sell and its value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset.

Where the carrying amount of an asset exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount. An impairment loss is recognised in profit or loss in the period in which it arises.

Deferred taxation

The deferred taxation charge takes into account taxation deferred due to timing differences between the treatment of certain items for taxation and accounting purposes.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events that result in an obligation to pay more, or a right to pay less, tax in the future have occurred at the balance sheet date, with the expectation that the Directors consider that it is more likely than not that there will be suitable taxable profits from which the future reversal of the underlying timing differences can be deducted. Deferred tax is measured on a non-discounted basis at the tax rates that are expected to apply in the periods in which timing differences reverse, based on tax rates and laws enacted or substantively enacted at the balance sheet date.

Borrowings

Borrowings are recognised initially at fair value, net of transaction cost incurred. Borrowings are subsequently stated at amortised cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognised in the profit and loss account over the period of the borrowings using the effective interest method. Finance costs, which are the difference between the net proceeds and the total amount of payments made in respect of the instruments, are spread on a straight line basis over the expected life of the debt.

Alliance Medical Acquisitionco Limited

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 30 September 2020

3. ACCOUNTING POLICIES (continued)

Financial instruments

The Company classifies financial instruments, or their component parts, on initial recognition as financial assets, financial liabilities or equity instruments according to the substance of the contractual arrangements entered into.

An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities. Equity instruments issued by the Company are recorded at the proceeds received, net of direct issue costs.

All financial instruments are initially recognised at fair value. After initial recognition, loans and receivables, including short-term receivables, and financial liabilities, including trade payables, are carried at amortised cost, as reduced by appropriate allowances for estimated irrecoverable amounts.

Foreign currencies

Transactions in foreign currencies are recorded at the rate ruling at the date of transaction or at the contracted rate if the transaction is covered by a forward foreign currency contract. Monetary assets and liabilities denominated in foreign currencies are retranslated at the rate of exchange ruling at the balance sheet date. All differences are taken to the profit and loss account.

Share capital

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares are shown in equity as a deduction from the proceeds received.

Critical accounting judgements and sources of estimation uncertainty

The preparation of financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported for assets and liabilities as at the balance sheet date and the amounts reported for revenues and expenses during the year.

Critical judgements in applying the Company's accounting policies

There were no critical accounting judgements that would have a significant effect on the amounts recognised in the Company Financial Statements.

Alliance Medical Acquisitionco Limited

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 30 September 2020

3. ACCOUNTING POLICIES (continued)

Key sources of estimation uncertainty

Contingent consideration

The Alliance Medical Acquisitionco acquired Life Molecular Imaging group (formerly known as Piramal Imaging) in 2018, consisting of 4 legal entities. As part of this acquisition, a large proportion of the consideration was contingent with a relatively small amount paid at the time of acquisition.

The contingent consideration will become payable when the acquired business is generating a positive cash contribution, measured on a cumulative basis from the date of acquisition. The contingent consideration is a 50% share of pre-tax cash generated for a period of 10 years post acquisition or a maximum payable of US\$200m. The amount included is the anticipated payment, based on long term forecasts, discounted to present value.

There are a number of factors which will impact the value of the contingent consideration and the directors have had to use their knowledge of the business along with certain judgements and estimates in order to value this consideration.

Forecasts have been completed to identify when the business is likely to become profitable, as well as the level of the profits, the profitability of this business also depends on the products created being given market authorisation and passing medical trials.

Alliance Medical Acquisitionco Limited

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 30 September 2020

4. OPERATING LOSS

This is stated after charging:

Auditors' remuneration for the audit of these financial statements of £5,500 (2019: £5,000).

5. STAFF NUMBERS AND COSTS

There were no staff, other than Directors, during the year (2019: nil).

6. DIRECTORS REMUNERATION AND TRANSACTIONS

The Directors have neither received nor waived any emoluments in respect of their services to the Company during the year (2019: £nil). The Directors of the Company are also, or have also been, Directors of one of more of the other companies in the Group. These Directors do not believe that it is practicable to apportion their emoluments between their services as Directors of the Company and their services as Directors of other companies in the Group.

7. INTEREST RECEIVABLE AND SIMILAR INCOME

	Year to 30 September 2020 £000	Year to 30 September 2019 £000
Bank interest	22	67
Interest receivable from fellow group undertakings	9,249	10,059
Net translation of foreign currency loans, receivables and payables	2,256	-
	<u>11,527</u>	<u>10,126</u>

8. INTEREST PAYABLE AND SIMILAR CHARGES

	Year to 30 September 2020 £000	Year to 30 September 2019 £000
Unwind of discounting of contingent consideration	3,193	2,402
Bank charges and fees	664	771
Amortisation of loan set up fee	1,882	949
Net translation of foreign currency loans, receivables and payables	-	1,767
Interest payable to fellow group undertakings	7,329	7,528
	<u>13,068</u>	<u>13,417</u>

Alliance Medical Acquisitionco Limited

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 30 September 2020

9. TAX ON LOSS

(a) Tax on loss

There is no charge for taxation in the year (2019: £nil).

(b) Factors affecting the tax for the year

The tax assessed for the year differs from (2019: differs from) that resulting from applying the standard rate of corporation tax in the UK of 19% (2019: 19%). The differences are explained below:

	Year to 30 September 2020 £000	Year to 30 September 2019 £000
Loss before tax	<u>(1,853)</u>	<u>(3,291)</u>
Loss at the standard rate of 19% (2019: 19%)	(352)	(625)
Effects of:		
Transfer pricing adjustment – imputed interest	259	-
Group relief surrendered for no consideration	<u>93</u>	<u>625</u>
Total tax for the year (note 7 (a))	<u>-</u>	<u>-</u>

(c) Factors affecting current and future tax charges

In the Spring Budget 2020, the Government announced that from 1 April 2020 the corporation tax rate would remain at 19% (rather than reducing to 17%, as previously enacted). This new law was substantively enacted on 17 March 2020. As the proposal to keep the rate at 19% was substantively enacted prior to the balance sheet date, its effects are included in these financial statements.

(d) Factors affecting the tax charge for the year

The Company has an unrecognised deferred tax asset in relation to tax losses of £19,533,000 (2019: £17,856,000). Deferred tax is not recognised as the future recovery of the asset is uncertain due to the difficulty in utilising these losses elsewhere in the group.

Alliance Medical Acquisitionco Limited

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 30 September 2020

10. INVESTMENTS

	Subsidiary Undertakings £000
Costs at 30 September 2020 and 30 September 2019	595,387
Impairment 30 September 2020 and 30 September 2019	(454,845)
Net book value at 30 September 2020 and 30 September 2019	140,542

These are analysed as:

Name	Country of incorporation	Value of investment in ordinary share capital £000	Effective % ownership	Principal activities
Alliance Medical Holdings Limited	England ^(A)	-	100	Management services
Alliance Medical Leasing Limited	England ^(A)	-	100	Finance Services
Alliance Medical Limited	England ^(A)	38,563	100	Medical diagnostic imaging services and parent of English operating subsidiaries
*Alliance Medical Radiopharmacy Limited	England ^(A)	-	100	Production of PET radio pharmaceuticals
*Alliance Medical Molecular Imaging Limited	England ^(A)	-	100	Production of PET radio pharmaceuticals
*Alliance Diagnostic Services Limited	England ^(A)	-	100	Medical diagnostic imaging services
*Lodestone Patient Care Limited	England ^(A)	-	100	Holding company
*Piramal Imaging Limited	England ^(A)	-	100	Development and production of PET radio pharmaceuticals
* Priamar srl ⁽¹⁾	Italy ^(Z)	-	100	Medical diagnostic imaging services
Alliance Medical Limited Sede secondaria	Italy ^(B)	-	100	Medical diagnostic imaging services
*Alliance Medical Italia S.r.l.	Italy ^(B)	78,367	100	Management services and parent of Italian operating subsidiaries
*Alliance Medical S.r.l.	Italy ^(B)	-	100	Medical diagnostic imaging services
Carried forward		<u>116,930</u>		

Alliance Medical Acquisitionco Limited
NOTES TO THE FINANCIAL STATEMENTS

For the year ended 30 September 2020

10. INVESTMENTS (continued)

Name	Country of incorporation	Value of investment in ordinary share capital £000	Effective % ownership	Principal activities
	Brought forward	116,930		
*Alliance Medical Technologies S.r.l.	Italy ^(B)	-	100	Medical diagnostic imaging services
*Alliance Medical Diagnostic S.r.l.	Italy ^(B)	-	100	Medical diagnostic imaging services
*Radioterapia Aurelia S.r.l.	Italy ^(B)	-	100	Medical diagnostic imaging services
*Opportunity srl	Italy ^(C)	-	100	Medical diagnostic imaging services
*Laboratorio Albaro srl	Italy ^(C)	-	100	Medical diagnostic imaging services
*Il Centro srl Diagnostica e Terapia Medica	Italy ^(D)	-	100	Medical diagnostic imaging services
*Centro Polispecialistico valli Stura e Orba Scrl	Italy ^(E)	-	100	Medical diagnostic imaging services
*Imed srl	Italy ^(V)	-	100	Medical diagnostic imaging services
*Centro Diagnostico Castellano srl	Italy ^(V)	-	100	Medical diagnostic imaging services
*Centro di Radiologia srl	Italy ^(W)	-	100	Medical diagnostic imaging services
*Centro Alfa srl	Italy ^(X)	-	100	Medical diagnostic imaging services
*Charter Medical Diagnostic Imaging Limited	Ireland ^(F)	-	100	Medical diagnostic imaging services
*Alliance Medical Diagnostic Imaging Limited	Ireland ^(F)	-	100	Management services and parent of Irish operating subsidiaries
*Alliance Medical Diagnostic Imaging (Northern Ireland) Limited	Ireland ^(F)	-	100	Medical diagnostic imaging services
*Cork Community Imaging Limited	Ireland ^(F)	-	100	Medical diagnostic imaging services
*Barringtons MRI Limited	Ireland ^(G)	-	50	Medical diagnostic imaging services
*20/20 Imaging Limited	Ireland ^(H)	-	33	Medical diagnostic imaging services
*BSM Diagnostica Gesellschaft mbH	Austria ^(R)	-	100	Production of PET radio pharmaceuticals
*Alliance Medical GmbH	Germany ^(I)	-	100	Medical diagnostic imaging services and parent of German operating subsidiaries
*Tomovation GmbH	Germany ^(I)	-	100	Medical diagnostic imaging services
*Life Radiopharma f-con GmbH	Germany ^(N)	-	67	Medical diagnostic imaging services
*Life Radiopharma Bonn GmbH	Germany ^(O)	-	100	Production of PET radio pharmaceuticals
*Life Radiopharma Berlin GmbH	Germany ^(Q)	-	100	Production of PET radio pharmaceuticals
*Life Molecular Imaging GmbH	Germany ^(S)	-	100	Development and production of PET radio pharmaceuticals
*Alliance Medical BV	Holland ^(J)	-	100	Medical diagnostic imaging services
*Life Radiopharma Warszawa SP Zoo	Poland ^(P)	-	100	Production of PET radio pharmaceuticals
	Carried forward	116,930		

Alliance Medical Acquisitionco Limited

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 30 September 2020

10. INVESTMENTS (continued)

Name	Country of incorporation	Value of investment in ordinary share capital £000	Effective % ownership	Principal activities
	Brought forward	116,930		
*Alliance-Servicos Diagnosticos por Imagen Unipessoal LDA	Portugal ^(K)	-	100	Dormant company
*Imagen Medical Digital Servicios Diagnosticos S.A.	Spain ^(L)	-	80	Medical diagnostic imaging services
*Alliance Medical La Rioja S.L.	Spain ^(M)	-	100	Medical diagnostic imaging services
Life Molecular Imaging SA	Switzerland ^(T)	23,612	100	Development and production of PET radio pharmaceuticals
*Life Molecular Imaging Inc	USA ^(U)	-	100	Development and production of PET radio pharmaceuticals
*European Scanning Centre (Harley Street) Limited	England ^(Y)	-	100	Medical diagnostic imaging services
*European Scanning Centre LLP (Harley Street)	England ^(Y)	-	84.5	Medical diagnostic imaging services
*European Scanning Centre LLP 2 (Harley Street)	England ^(Y)	-	92.5	Medical diagnostic imaging services
*European Scanning Centre LLP MSK (Harley Street)	England ^(Y)	-	97	Medical diagnostic imaging services
*European Scanning Centre LLP (Manchester)	England ^(Y)	-	98.5	Medical diagnostic imaging services
*European Scanning Centre LLP (Cardiff)	England ^(Y)	-	100	Medical diagnostic imaging services
	*held indirectly	<u>140,542</u>		

⁽¹⁾ Acquired 31 December 2019

Alliance Medical Acquisitionco Limited

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 30 September 2020

10. INVESTMENTS (continued)

The registered office of the investments are as follows:

- (A) Icen Centre, Warwick Technology Park, Warwick, Warwickshire, CV34 6DA
- (B) Via G. Mameli 42/A, 20851, Lissone, Italy
- (C) Via Paolo Boselli 32/6, 16146, Genova, Italy
- (D) Piazza Dante 9/10, 16121, Genova, Italy
- (E) Via Vallecaldà 45, 16013, Campo Ligure, Italy
- (F) Portal House, Loughmore Avenue, Raheen Business Park, Limerick, Ireland
- (G) Barringtons Hospital, Georges Quay, Limerick Ireland
- (H) 82 North Main Street, Bandon, Co. Cork, Ireland
- (I) Westring 168, 44575 Castrop-Rauxel, Germany
- (J) PO Box 1768, NL-3800 BT Amersfoort, Netherlands
- (K) Avda. Antonio Augusto de Aguilar, 150-5 Dto. 1050-022 Lisboa, Portugal
- (L) Calle Illa, Num. 52 Planta Bajo. 08202 Sabadell, Barcelona, Spain
- (M) Avda. Portugal, Num. 23 Planta 1, Despacho 2, 26001 Logrono, Spain
- (N) Nic.-Aug.-Otto-Str. 7a, D-12489, Berlin, Germany
- (O) Spessartstr. 9, D-53119 Bonn, Germany
- (P) Ul. Szeligowska 3, PL-05-850 Szeligi, Poland
- (Q) Max-Planck-Strabe 4, D-12489 Berlin
- (R) Alser strasse 25, A-1080 Wien, Austria
- (S) Tegeler Strasse 6-7, 13353 Berlin, Germany
- (T) 13 Route de l'Ecole, 1753 Matran, Switzerland
- (U) C/o The Corporation Trust Company, 1209 Orange Street, Wilmington, Delaware 19801, New Castle County, USA
- (V) Via Alfieri 13, 35125 Padova, Italy
- (W) Via Zenson di Piave, 31100 Treviso, Italy
- (X) Via Bellini 174, 41121 Modena, Italy
- (Y) 68 Harley Street, London, W1G 7HE
- (Z) Via Partigiani, 13/r - 17100 Savona, Italy

A review of investments in subsidiaries was performed during the year and, as a result, £nil (2019: £nil) of the Company's investment in its subsidiaries was identified as being impaired. The Directors believe that the carrying value of the investments is supported by their underlying net assets and future cash flows.

Alliance Medical Acquisitionco Limited

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 30 September 2020

11. DEBTORS

	As at 30 September 2020 £000	As at 30 September 2019 £000
Amounts owed by Group undertakings	<u>225,758</u>	<u>213,116</u>
	225,758	213,116

Amounts owed by overseas Group undertakings of £74,667,000 (2019: £74,299,000), are unsecured, subject to formal loan agreements and are repayable on demand. Interest in respect of these amounts and amounts owed by overseas Group undertakings to fellow UK-based group undertakings, are payable to the Company at a rate of 5% per annum.

Amounts owed by UK Group undertakings of £151,091,000 (2019: £138,817,000) are unsecured and are repayable on demand. £119,957,000 (2019: £109,927,000) of this amount is interest bearing and these amounts are payable to the Company at a rate of 5% per annum. The remaining £31,134,000 (2019: £28,890,000) is not interest bearing.

12. CREDITORS

a) Amounts falling due within one year:

	As at 30 September 2020 £000	As at 30 September 2019 £000
Amounts owed to group undertakings	<u>19,027</u>	<u>19,634</u>
	19,027	19,634

Amounts owed to Group undertakings were unsecured, interest free and were repayable on demand

b) Amounts falling due after more than one year:

	As at 30 September 2020 £000	As at 30 September 2019 £000
Borrowings	228,718	202,498
Contingent consideration	<u>29,158</u>	<u>27,162</u>
	257,876	229,660

The contingent consideration relates to the acquisition of the Life Molecular Imaging SA group on 25 June 2018. The contingent consideration will become payable when the acquired business is generating a positive cash contribution, measured on a cumulative basis, from the date of acquisition. The contingent consideration is a 50% share of the pre-tax cash generated for a period of 10 years post-acquisition or a maximum of US\$200m. The amount included is the anticipated payment, based on long term forecasts, discounted to present value and retranslated to the foreign exchange rate in force at 30 September 2020.

Alliance Medical Acquisitionco Limited

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 30 September 2020

12. CREDITORS (continued)

c) Borrowings

The maturity profile of the borrowings is:

	As at 30 September 2020 £000	As at 30 September 2019 £000
Between two and five years	228,718	204,380
Unamortised issue costs	-	(1,882)
	<u>228,718</u>	<u>202,498</u>

The borrowings comprise a loan from Life UK Healthcare Limited, a parent undertaking, which is subject to interest at LIBOR plus a margin of 2.85%.

13. CALLED UP SHARE CAPITAL AND RESERVES

	2020 No.	2020 £000	2019 No.	2019 £000
Ordinary shares of £1 each				
Authorised	<u>147,537,013</u>	<u>147,537</u>	<u>147,537,013</u>	<u>147,537</u>
Allotted, called up and fully paid	<u>147,537,013</u>	<u>147,537</u>	<u>147,537,013</u>	<u>147,537</u>

There are no restrictions on the payment of dividends and the repayment of capital.

The profit and loss reserve represents cumulative profits or losses, including unrealised profit on the re-measurement of investment properties, net of dividends paid and other adjustments.

14. RELATED PARTY TRANSACTIONS

There have been no related party transactions other than transactions with fellow subsidiaries of the Life Healthcare Group Holdings Limited group, including the interest bearing loan from Life UK Healthcare Limited (note 10).

In accordance with FRS 102, the company has taken advantage of the exemption available not to disclose transactions with other group undertakings.

Alliance Medical Acquisitionco Limited

NOTES TO THE FINANCIAL STATEMENTS

For the year ended 30 September 2020

15. PARENT UNDERTAKINGS

The immediate parent company is Alliance Medical Group Limited and the ultimate parent undertaking is Life Healthcare Group Holdings Limited. The smallest group for which group financial statements are drawn up and which include this company is Alliance Medical Group Limited, registered in England and Wales. The financial statements can be obtained by writing to the Secretary at Icen Centre, Warwick Technology Park, Warwick, CV34 6DA, its registered address. The largest group for which group financial statements are drawn up is Life Healthcare Group Holdings Limited, registered in South Africa. The financial statements can be obtained by writing to the Secretary at Oxford Manor, 21 Chaplin Road, Illovo, Guateng, South Africa, 2196, its registered address.

16. POST BALANCE SHEET EVENTS

The Covid pandemic is considered to remain a significant event after the balance sheet date, even though it has also impacted the group in this financial year. The impact of Covid is still being felt across the globe within the healthcare industry, including the countries that Alliance Medical Group operate in. Following the balance sheet date, a number of European Countries, including the UK, has entered second national lock down. The effects of Covid are still felt around the business, however volumes are almost back to 100% of pre-Covid levels and systems and protocols put in place during wave 1 of the pandemic now mean that the business can continue to operate at a more effective level during the ongoing Covid impacts. This is as well as opportunities taken as a result of the pandemic, have meant that the directors do not believe that the effects of Covid post the balance sheet date lead to a material impact in the numbers presented and therefore no adjustments are required.

As well as the above there are ongoing discussions between the UK and the EU in relation to a trade deal following the UKs exit from the EU effective from 1 January 2021. Currently there are no details regarding the likelihood or the contents of such a deal. As a result it cannot be estimated what impacts Brexit will have on the Company and therefore no changes have been made to these financial statements.